NASDAQ:ONTX Onconova Therapeutics (ONTX) Stock Forecast, Price & News $1.18 -0.02 (-1.67%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$1.18▼$1.2350-Day Range$0.67▼$1.4252-Week Range$0.62▼$1.52Volume57,861 shsAverage Volume437,829 shsMarket Capitalization$24.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Onconova Therapeutics MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.39% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.37Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.21) to ($0.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.56 out of 5 starsMedical Sector858th out of 981 stocksPharmaceutical Preparations Industry406th out of 464 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Onconova Therapeutics. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.39% of the outstanding shares of Onconova Therapeutics have been sold short.Short Interest Ratio / Days to CoverOnconova Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Onconova Therapeutics has recently decreased by 24.78%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOnconova Therapeutics does not currently pay a dividend.Dividend GrowthOnconova Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONTX. Previous Next 1.9 News and Social Media Coverage News SentimentOnconova Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Onconova Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ONTX on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Onconova Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of Onconova Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 8.30% of the stock of Onconova Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Onconova Therapeutics are expected to grow in the coming year, from ($1.21) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Onconova Therapeutics is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Onconova Therapeutics is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOnconova Therapeutics has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Onconova Therapeutics (NASDAQ:ONTX) StockOnconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.Read More Receive ONTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ONTX Stock News HeadlinesJune 7, 2023 | msn.comHC Wainwright & Co. Reiterates Onconova Therapeutics (ONTX) Prior RecommendationJune 6, 2023 | markets.businessinsider.comOnconova Therapeutics (ONTX) Receives a Buy from H.C. WainwrightJune 7, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.June 5, 2023 | finance.yahoo.comOnconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual MeetingMay 31, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Onconova Therapeutics (NASDAQ:ONTX)May 27, 2023 | americanbankingnews.comOnconova Therapeutics, Inc. (NASDAQ:ONTX) Short Interest UpdateMay 25, 2023 | finance.yahoo.comOnconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint BlockadeMay 24, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Onconova Therapeutics (NASDAQ:ONTX)June 7, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 20, 2023 | americanbankingnews.comOnconova Therapeutics, Inc. Forecasted to Earn Q2 2023 Earnings of ($0.29) Per Share (NASDAQ:ONTX)May 19, 2023 | americanbankingnews.comAnalysts Issue Forecasts for Onconova Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ONTX)May 17, 2023 | marketwatch.com8-K: Onconova Therapeutics, Inc.May 16, 2023 | msn.comHC Wainwright & Co. Reiterates Onconova Therapeutics (ONTX) Buy RecommendationMay 16, 2023 | markets.businessinsider.comOnconova Therapeutics (ONTX) Gets a Buy from Noble FinancialMay 16, 2023 | finanznachrichten.deOnconova Therapeutics, Inc.: Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX), Cara Therapeutics (CARA) and Minerva Neurosciences (NERV)May 16, 2023 | finance.yahoo.comQ1 2023 Onconova Therapeutics Inc Earnings CallMay 15, 2023 | msn.comOnconova Therapeutics: Q1 Earnings InsightsMay 15, 2023 | finance.yahoo.comOnconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue EstimatesMay 15, 2023 | investing.comOnconova Therapeutics (ONTX) Earnings Dates & ReportsMay 15, 2023 | finance.yahoo.comOnconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 14, 2023 | americanbankingnews.comOnconova Therapeutics (NASDAQ:ONTX) Receives New Coverage from Analysts at StockNews.comMay 12, 2023 | finance.yahoo.comOnconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial CancerMay 11, 2023 | finance.yahoo.comOnconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial CancerMay 8, 2023 | americanbankingnews.comOnconova Therapeutics (ONTX) to Release Earnings on MondayMay 8, 2023 | finance.yahoo.comOnconova Therapeutics to Present at the ISID International Epidermolysis Bullosa SymposiumMay 6, 2023 | americanbankingnews.comOnconova Therapeutics (NASDAQ:ONTX) Research Coverage Started at StockNews.comSee More Headlines ONTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONTX Company Calendar Last Earnings3/16/2023Today6/07/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONTX CUSIPN/A CIK1130598 Webwww.onconova.com Phone(267) 759-3680Fax267-759-3681Employees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,960,000.00 Net Margins-9,122.57% Pretax Margin-9,122.57% Return on Equity-67.03% Return on Assets-49.59% Debt Debt-to-Equity RatioN/A Current Ratio3.80 Quick Ratio3.80 Sales & Book Value Annual Sales$226,000.00 Price / Sales112.74 Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book0.90Miscellaneous Outstanding Shares20,970,000Free Float20,718,000Market Cap$25.48 million OptionableNot Optionable Beta1.78 Key ExecutivesSteven M. FruchtmanPresident, Chief Executive Officer & DirectorMark P. GuerinChief Operating & Financial OfficerMatthew ParrisVice President-Clinical OperationsMichael SaundersChief Medical OfficerAdar Makovski SilversteinSenior Director & Head-Corporate DevelopmentKey CompetitorsCocrystal PharmaNASDAQ:COCPMetacrineNASDAQ:MTCRLipocineNASDAQ:LPCNAcasti PharmaNASDAQ:ACSTVaccinexNASDAQ:VCNXView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCSold 22,852 shares on 5/12/2023Ownership: 0.690%Simplex Trading LLCSold 100 shares on 4/27/2023Ownership: 0.000%View All Institutional Transactions ONTX Stock - Frequently Asked Questions Should I buy or sell Onconova Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ONTX shares. View ONTX analyst ratings or view top-rated stocks. How have ONTX shares performed in 2023? Onconova Therapeutics' stock was trading at $0.6457 at the start of the year. Since then, ONTX shares have increased by 88.2% and is now trading at $1.2150. View the best growth stocks for 2023 here. Are investors shorting Onconova Therapeutics? Onconova Therapeutics saw a drop in short interest in May. As of May 15th, there was short interest totaling 291,400 shares, a drop of 24.8% from the April 30th total of 387,400 shares. Based on an average daily volume of 540,800 shares, the short-interest ratio is presently 0.5 days. View Onconova Therapeutics' Short Interest. When is Onconova Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our ONTX earnings forecast. How were Onconova Therapeutics' earnings last quarter? Onconova Therapeutics, Inc. (NASDAQ:ONTX) posted its quarterly earnings data on Thursday, March, 16th. The biopharmaceutical company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.01. The biopharmaceutical company earned $0.06 million during the quarter, compared to analysts' expectations of $0.08 million. Onconova Therapeutics had a negative net margin of 9,122.57% and a negative trailing twelve-month return on equity of 67.03%. When did Onconova Therapeutics' stock split? Shares of Onconova Therapeutics reverse split on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Onconova Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM). What is Onconova Therapeutics' stock symbol? Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX." Who are Onconova Therapeutics' major shareholders? Onconova Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.69%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Abraham N Oler, Abraham N Oler, E Premkumar Reddy, James J Marino, Mark Patrick Guerin and Steven M Fruchtman. View institutional ownership trends. How do I buy shares of Onconova Therapeutics? Shares of ONTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Onconova Therapeutics' stock price today? One share of ONTX stock can currently be purchased for approximately $1.22. How much money does Onconova Therapeutics make? Onconova Therapeutics (NASDAQ:ONTX) has a market capitalization of $25.48 million and generates $226,000.00 in revenue each year. The biopharmaceutical company earns $-18,960,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. How can I contact Onconova Therapeutics? Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The official website for the company is www.onconova.com. The biopharmaceutical company can be reached via phone at (267) 759-3680, via email at ir@onconova.us, or via fax at 267-759-3681. This page (NASDAQ:ONTX) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconova Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.